Effects of anti-IL-6 receptor antibody on human monocytes

References

• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–42.
   PubMed Web of Science ®Google Scholar
• Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther. 2006;8(Suppl 2):S4.
   Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–9.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48(4):927–34.
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46(12):3143–50.
   PubMed Web of Science ®Google Scholar
• Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, et al. Brief report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(8):2499–503.
   PubMed Web of Science ®Google Scholar
• Tejima S, Tono T, Nagai T, Hirohata S. Differential in vitro effects of biological agents on cytokine production of peripheral blood mononuclear cells. Kitasato Medical J. 2013;43(2):126–32.
   Google Scholar
• Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A. Retinoicacid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol. 1991;146(11):3809–14.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(7):1208–15.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58(5):1248–57.
   PubMed Web of Science ®Google Scholar
• Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol. 2013. (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Curnow SJ, Glennie MJ, Stevenson GT. The role of in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother. 1993;36(3):149–55.
   PubMed Web of Science ®Google Scholar
• Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F, et al.Targeting monocyte/macrophages in the treatment of rheumatoid arthritis. Rheumatology. 2013;52(4):590–8.
   PubMed Web of Science ®Google Scholar
• Mandron M, Ariès MF, Boralevi F, Martin H, Charveron M, Taieb A, et al. Age-related differences in sensitivity of peripheral blood monocytes to lipopolysaccharide and Staphylococcus aureus toxin B in atopic dermatitis. J Invest Dermatol. 2008;128(4):882–9.
   PubMed Web of Science ®Google Scholar
• Iwahashi M, Yamamura M, Aita T, Okamoto A, Ueno A, Ogawa N, et al. Expression of Toll-like receptor 2 on CD16 + blood monocytes and synovial tissue macrophage in rheumatoid arthritis. Arthritis Rheum. 2004;50(5):1457–67.
   PubMed Web of Science ®Google Scholar
• Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-18 via interferon-gamma. Arthritis Rheum. 2004;50(12):3856–65.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Stuhlmüller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?Arthritis Rheum. 1997;40(1):5–18.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Yanagida T, Itoh K, Nakamura H, Yoshino S, Tomita T, et al. Accelerated generation of CD14 + monocyte-lineage cells from the bone marrow of rheumatoid arthritis patients. Arthritis Rheum. 1996;39(5):836–43.
   PubMed Web of Science ®Google Scholar
• Kappler J, Kotzin B, Herron L, Gelfand EW, Bigler RD, Boylston A, et al. V beta-specific stimulation of human T cells by staphylococcal toxins. Science. 1989;244(4906):811–3.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?Annu Rev Immunol. 2001;19:163–96.
   PubMed Web of Science ®Google Scholar
• Wong PKK, Campbell IK, Egan PJ, Ernst M, Wicks IP. The roll of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum. 2003;48(5):1177–1889.
   PubMed Web of Science ®Google Scholar
• Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol. 2013;32:1661–1136.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, et al. Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. Ann Rheum Dis. 2012;71(9):1583–5.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Nakahara H. The possibility of tocilizumab cessation in patients who have respond to tocilizumab. J Clin Exp Med. 2010;234(1):110–4.
   Google Scholar